Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
08 févr. 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
19 janv. 2017 02h00 HE
|
Dermira, Inc.
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trialsSubmission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and...
Dermira Provides Corporate Update
06 janv. 2017 07h30 HE
|
Dermira, Inc.
Treatment period for DRM04 ARIDO trial completedPhase 3 acne clinical program for olumacostat glasaretil initiatedTopline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected...
Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
05 janv. 2017 07h30 HE
|
Dermira, Inc.
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership TeamWorked on several leading dermatology brands including ACZONE® and BOTOX® during...
Dermira Elects Emmanuel Caeymaex to Board of Directors
04 janv. 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Initiates Phase 3 Clinical Program in Acne
03 janv. 2017 07h30 HE
|
Dermira, Inc.
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgarisTwo Phase 3 trials expected to enroll a total of 1,400...
Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
08 déc. 2016 02h00 HE
|
Dermira, Inc.
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development programFindings confirm CIMZIA results observed in earlier CIMPASI-2 trialResults from third and...
Dermira to Present at Stifel 2016 Healthcare Conference
09 nov. 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
07 nov. 2016 16h07 HE
|
Dermira, Inc.
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to...
Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
21 oct. 2016 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...